Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics

Alméras, Natalie; Després, Jean‐Pierre; Villeneuve, Julie; Demers, Marie-France; Roy, Marc‐André; Cadrin, Camille; Mottard, Jean-Pierre; Bouchard, Roch-Hugo

doi:10.4088/jcp.v65n0417

Cited by 51 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Olanzapine also induces an increase in waist circumference in humans (Almeras et al 2004;Gothelf et al 2002). Changes in central fat deposition in both rodents and humans may be modulated by a number of key regulatory hormones.…”

Section: Variablementioning

confidence: 97%

A parametric analysis of olanzapine-induced weight gain in female rats

et al. 2005

View full text Add to dashboard Cite

These data suggest that aspects of olanzapine-induced weight gain and metabolic abnormalities can possibly be modelled in female rats. It is suggested that olanzapine-induced hyperphagia acts as an initial stimulus which leads to weight gain, enhanced visceral adiposity and subsequent insulin resistance, although the latter may be ameliorated by compensatory responses in adiponectin levels. Prolactin elevation appears likely not to be involved in the weight gain, adiposity and metabolic changes seen in this model.

show abstract

Section: Variablementioning

confidence: 97%

A parametric analysis of olanzapine-induced weight gain in female rats

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The lack of further studies on drug-naïve patients is an anticipated source of bias in any effort to explore the role of antipsychotic medication in the development of MetS. However, numerous studies attempted to compare various antipsychotics or groups of antipsychotics (FGAs versus SGAs) in terms of their contribution to MetS [Almeras et al 2004;Kato et al 2004;Straker et al 2005;Correll et al 2006Correll et al , 2007Hagg et al 2006;L'Italien et al 2007;Suvisaari et al 2007;Tirupati et al 2007;Cerit et al 2008;De Hert et al 2008b;Meyer et al 2008;Saddichha et al 2008;Huang et al 2009;Rezaei et al 2009;Schorr et al 2009;Lee et al 2011]. Consistent findings across these studies found that MetS was more likely with SGAs over FGAs, polypharmacy over monopharmacy and high-potency over low-potency agents.…”

Section: Metabolic Syndrome and Medicationmentioning

confidence: 99%

The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

Papanastasiou¹

2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Metabolic syndrome: introduction The metabolic syndrome (MetS, also known as syndrome X, syndrome of chronic cardiovascular disease and Reaven's syndrome) is a constellation of different conditions, including abdominal obesity, insulin resistance, dyslipidaemia and elevated blood pressure. All components of the MetS (with obesity holding a central role in its development) have been recognized as independent risk factors for cardiovascular disease and so the presence of MetS is associated with other comorbidities such as the prothrombotic state, proinflammatory state, nonalcoholic fatty liver disease and reproductive disorders [Cornier et al. 2008]. Owing to its multiple components, many definitions have

show abstract

“…Meyer 48 compared patients taking risperidone and olanzapine after 1 year of treatment and found increased total cholesterol and triglycerides significantly higher with olanzapine. Alméras et al 55 assessed patients taking olanzapine and risperidone for 6 months. Use of olanzapine was associated with higher triglyceridemia, increased levels of apolipoprotein B, lower HDL levels and smaller LDL particle diameter, compared with use of risperidone or control group.…”

Section: Etiologic Factorsmentioning

confidence: 99%

Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor

Teixeira¹,

Rocha

2006

Rev. psiquiatr. Rio Gd. Sul

View full text Add to dashboard Cite

INTRODUÇÃO: Um aumento na incidência de obesidade e diabetes melito entre pacientes psiquiátricos foi observado ainda na década de 60, como resultado indesejável do uso de antipsicóticos. Nos anos 80 e 90, a reabilitação da clozapina, a síntese dos demais antipsicóticos atípicos e a disseminação do uso do lítio e do ácido valpróico chamaram novamente a atenção para os efeitos metabólicos desses medicamentos. Este estudo tem por objetivo revisar a literatura médica a respeito dos efeitos adversos metabólicos associados ao uso de antipsicóticos e estabilizadores de humor. MÉTODO: Foi realizada uma extensa pesquisa nas bases de dados MEDLINE e LILACS até outubro de 2005. CONCLUSÃO: Os efeitos adversos metabólicos permanecem como problemas importantes da psicofarmacologia. Ganho de peso clinicamente relevante ocorre com freqüência em pacientes em uso de antipsicóticos e estabilizadores de humor, principalmente naqueles em uso de clozapina, olanzapina, lítio e ácido valpróico. A clozapina e a olanzapina associam-se também a uma maior incidência de diabetes melito e dislipidemias, seja devido ao ganho de peso, seja por ação deletéria direta sobre o metabolismo da glicose. A incidência de obesidade e outros distúrbios metabólicos é menor com a risperidona, se comparada à olanzapina ou à clozapina. Carbamazepina associa-se a menor ganho de peso, se comparada ao lítio ou ao ácido valpróico. Drogas como o haloperidol, a ziprasidona, o aripiprazol e a lamotrigina não estão associadas a ganho importante de peso ou a maior incidência de diabetes melito e são alternativas para pacientes mais propensos a desenvolver tais efeitos adversos.

show abstract

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics

Cited by 51 publications

References 0 publications

A parametric analysis of olanzapine-induced weight gain in female rats

A parametric analysis of olanzapine-induced weight gain in female rats

The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor

Contact Info

Product

Resources

About